CAS: 18358-63-9; Methyl 4-(Methylamino)Benzoate

上下游产品

CAS号67-56-1 甲醇 | CAS号10541-83-0 4-甲氨基苯甲酸 | CAS号619-45-4 4-氨基苯甲酸甲酯 | CAS号74-88-4 碘甲烷 | CAS号741275-29-6 methyl 4-(tert-... | CAS号881005-27-2 methyl N-methyl... | CAS号68-11-1 硫代乙醇酸(TGA) | CAS号94341-53-4 methyl 4-(azido... | CAS号150-13-0 对氨基苯甲酸 | CAS号108191-10-2 4-(methylamino)... | CAS号108191-11-3 N-benzyl-4-(met... | CAS号181819-75-0 (4-(methylamino... | CAS号128742-76-7 1-甲基-5-吲哚甲酸甲酯 | CAS号556-21-8 4-(甲基氨基)苯甲醛

Methyl 4-(Azidomethyl)Benzoate置于三乙基硅烷,四氯化锡体系中,用 二氯甲烷 用作溶剂,以40%的收率获得4-(甲氨基)苯甲酸甲酯
参考文献:来自苄基叠氮化物的n-甲基苯胺
标题:来自苄基叠氮化物的n-甲基苯胺
摘要:在布朗斯台德酸或路易斯酸和et 3 Sih的存在下,苄基叠氮化物可有效地转化为n-甲基苯胺.叠氮化物和4-正丁基苄基叠氮化物的组合似乎形成了氨基重氮三氯锡酸酯(II),该重氮经历重排成亚胺盐,然后被et 3 Sih还原为n-甲基-4-正丁基苯胺.
Doi:10.1016/s0040-4039(99)00148-3

专利信息

专利号:US-2002156277-A1
优先权日:2001-04-20
标题 :Synthesis and methods of use of purine analogues and derivatives
发明人：FICK DAVID B; FOREMAN MARK M; GLASKY ALVIN J
摘要:A purine derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y 1 )—D, where Y 1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can have one, two, or three nitrogen atoms in the five membered ring and has two nitrogen atoms in the six-membered ring. The moiety A can be a purine moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity.

专利号:US-6207836-B1
优先权日:1993-02-17
标 题 :Indolin-2-one derivatives
发明人：ESAKI TORU; EMURA TAKASHI; HOSHINO EIICHI
权利人:CHUGAI PHARMACEUTICAL CO LTD
摘要:A compound represented by formula (I):wherein R1 represents a halogen atom, a lower alkyl group, a lower alkoxy group, a hydroxyl group, a nitro group, a trifluoromethyl group, a lower alkylthio group, an acyl group, a carboxyl group, a mercapto group or an amino group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an alkoxy group, an acyl group, an aryl group or a heterocyclic group; R3 represents a lower alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; R4 represents a hydrogen atom, a lower alkyl group, an aryl group, a heterocyclic group, -OR5, -SR5 or -NR6R7 (wherein R5, R6, and R7 each represent a lower alkyl group, etc.); X and Y each represent -CH2-, -NH- or -O-; and n represents an integer of from 0 to 4, and an intermediate for synthesis thereof are disclosed. The compound of the present invention exhibits selective antagonism against gastrin receptors without causing side effects attributed to CCK-A receptor antagonism and is useful for the treatment and prevention of peptic ulcers, gastritis, reflux esophagitis, and Zollinger-Ellison syndrome, and for the treatment of neoplasm originating in the gastrointestinal system.